An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases

Urology

Volumn 52, Issue 3, 1998, Pages 455-461

  Carlson, Grant D ^a   Calvanese, Christina B ^b   Partin, Alan W ^b  

^a Dianon Systems   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGE FACTORS; AGED; ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0032169315     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00205-2     Document Type: Article

References (23)

1. 1. Wingo PA, Landis S, and Ries LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 47: 239-242, 1997.
2. 2. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
3. 3. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979.
4. 4. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
5. 5. Lange PH, Ercole CJ, Lightner DJ, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873-879, 1989.
6. 6. Hudson MA, Bahnson RR, and Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011-1017, 1989.
7. 7. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
8. 8. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign prostatic hyperplasia: diagnosis and treatment. Quick reference guide for clinicians. AHCPR Publication No. 94-0583. Rockville, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, February 1994.
9. 9. Catalona WJ, Partin AW, Slawin KM, et al: A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease (abstract). J Urol 157(suppl): 111, 1997.
10. 10. Luderer AA, Chen YT, Soriano TF, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of prostate-specific antigen. Urology 47: 518-524, 1995.
11. 11. Hosmer DW, and Lemeshow S: Applied Logistic Regression. New York, John Wiliey & Sons, 1989.
12. 12. SPSS Advanced Statistics 7.5, Chicago, SPSS, 1997.
13. 13. Cooner WH, Mosley BR, Rutherford CL Jr, et al: Prostate cancer detection in a clinical urology practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143: 1146-1154, 1990.
14. 14. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
15. 15. Lilja H, Christensson A, Dahlen U, et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
16. 16. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
17. 17. Christensson A, Bjork T, Nilsson O, et al: Serum prostate-specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
18. 18. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 274: 1214-1220, 1995.
19. 19. Chen YT, Luderer AA, Thiel RP, et al: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
20. 20. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49: 19-27, 1997.
21. 21. Elgamal A, Cornillie FJ, Van Poppel HP, et al: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 156: 1042-1049, 1996.
22. 22. Kirollos MM: Statistical review and analysis of the relationship between serum prostate specific antigen and age. J Urol 158: 143-145, 1997.
23. 23. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (suppl 6A):55-61, 1996.